

# Lars H Lund

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7856514/publications.pdf>

Version: 2024-02-01

384  
papers

36,624  
citations

7551

77  
h-index

3997

176  
g-index

391  
all docs

391  
docs citations

391  
times ranked

26621  
citing authors

#	ARTICLE	IF	CITATIONS
1	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 2021, 42, 3599-3726.	1.0	5,558
2	2018 ESC/EACTS Guidelines on myocardial revascularization. European Heart Journal, 2019, 40, 87-165.	1.0	4,537
3	Global Public Health Burden of Heart Failure. Cardiac Failure Review, 2017, 03, 7.	1.2	1,731
4	The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: A 10-year update. Journal of Heart and Lung Transplantation, 2016, 35, 1-23.	0.3	1,096
5	Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. New England Journal of Medicine, 2021, 384, 117-128.	13.9	1,080
6	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Journal of Heart Failure, 2022, 24, 4-131.	2.9	820
7	The Registry of the International Society for Heart and Lung Transplantation: Thirty-fourth Adult Heart Transplantation Reportâ€™2017; Focus Theme: Allograft ischemic time. Journal of Heart and Lung Transplantation, 2017, 36, 1037-1046.	0.3	645
8	The Registry of the International Society for Heart and Lung Transplantation: Thirty-fourth Adult Lung And Heart-Lung Transplantation Reportâ€™2017; Focus Theme: Allograft ischemic time. Journal of Heart and Lung Transplantation, 2017, 36, 1047-1059.	0.3	624
9	The Registry of the International Society for Heart and Lung Transplantation: Thirtieth Official Adult Heart Transplant Reportâ€™2013; Focus Theme: Age. Journal of Heart and Lung Transplantation, 2013, 32, 951-964.	0.3	561
10	Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2018, 20, 1505-1535.	2.9	555
11	The Registry of the International Society for Heart and Lung Transplantation: Thirty-third Adult Heart Transplantation Reportâ€™2016; Focus Theme: Primary Diagnostic Indications for Transplant. Journal of Heart and Lung Transplantation, 2016, 35, 1158-1169.	0.3	522
12	Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovascular Research, 2023, 118, 3272-3287.	1.8	517
13	The Registry of the International Society for Heart and Lung Transplantation: Thirty-first Official Adult Heart Transplant Reportâ€™2014; Focus Theme: Retransplantation. Journal of Heart and Lung Transplantation, 2014, 33, 996-1008.	0.3	490
14	The Registry of the International Society for Heart and Lung Transplantation: Thirtieth Adult Lung and Heart-Lung Transplant Reportâ€™2013; Focus Theme: Age. Journal of Heart and Lung Transplantation, 2013, 32, 965-978.	0.3	479
15	The Registry of the International Society for Heart and Lung Transplantation: Thirty-second Official Adult Lung and Heart-Lung Transplantation Reportâ€™2015; Focus Theme: Early Graft Failure. Journal of Heart and Lung Transplantation, 2015, 34, 1264-1277.	0.3	465
16	The Registry of the International Society for Heart and Lung Transplantation: Thirty-second Official Adult Heart Transplantation Reportâ€™2015; Focus Theme: Early Graft Failure. Journal of Heart and Lung Transplantation, 2015, 34, 1244-1254.	0.3	464
17	The Registry of the International Society for Heart and Lung Transplantation: Thirty-first Adult Lung and Heartâ€™Lung Transplant Reportâ€™2014; Focus Theme: Retransplantation. Journal of Heart and Lung Transplantation, 2014, 33, 1009-1024.	0.3	451
18	2018 ESC/EACTS Guidelines on myocardial revascularization. European Journal of Cardio-thoracic Surgery, 2019, 55, 4-90.	0.6	402

#	ARTICLE	IF	CITATIONS
19	Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction: PROMIS-HFpEF. <i>European Heart Journal</i> , 2018, 39, 3439-3450.	1.0	375
20	Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure. <i>Circulation</i> , 2020, 141, 352-361.	1.6	335
21	Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. <i>European Journal of Heart Failure</i> , 2018, 20, 1230-1239.	2.9	295
22	2019 EACTS Expert Consensus on long-term mechanical circulatory support. <i>European Journal of Cardio-thoracic Surgery</i> , 2019, 56, 230-270.	0.6	255
23	Epidemiology, pathophysiology and contemporary management of cardiogenic shock—A position statement from the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2020, 22, 1315-1341.	2.9	244
24	Right heart dysfunction and failure in heart failure with preserved ejection fraction: mechanisms and management. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2018, 20, 16-37.	2.9	239
25	Atrial Fibrillation in Heart Failure With Preserved, Mid-Range, and Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2017, 5, 565-574.	1.9	236
26	Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2019, 21, 553-576.	2.9	224
27	Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. <i>European Journal of Heart Failure</i> , 2019, 21, 827-843.	2.9	223
28	The Registry of the International Society for Heart and Lung Transplantation: Sixteenth Official Pediatric Heart Transplantation Report—2013; Focus Theme: Age. <i>Journal of Heart and Lung Transplantation</i> , 2013, 32, 979-988.	0.3	201
29	A comprehensive population-based characterization of heart failure with mid-range ejection fraction. <i>European Journal of Heart Failure</i> , 2017, 19, 1624-1634.	2.9	196
30	Prognostic implications of atrial fibrillation in heart failure with reduced, mid-range, and preserved ejection fraction: a report from 14 964 patients in the European Society of Cardiology Heart Failure Long-Term Registry. <i>European Heart Journal</i> , 2018, 39, 4277-4284.	1.0	189
31	Self-care of heart failure patients: practical management recommendations from the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2021, 23, 157-174.	2.9	181
32	Significance of Ischemic Heart Disease in Patients With Heart Failure and Preserved, Midrange, and Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2017, 10, .	1.6	177
33	Acute heart failure congestion and perfusion status—Impact of the clinical classification on in-hospital and long-term outcomes; insights from the ESC-EORP-HFA Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2019, 21, 1338-1352.	2.9	170
34	Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2021, 23, 872-881.	2.9	160
35	Role of cardiopulmonary exercise testing in clinical stratification in heart failure. A position paper from the Committee on Exercise Physiology and Training of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2018, 20, 3-15.	2.9	157
36	Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry. <i>European Journal of Heart Failure</i> , 2018, 20, 1326-1334.	2.9	156

#	ARTICLE	IF	CITATIONS
37	Heart failure with mid-range or mildly reduced ejection fraction. <i>Nature Reviews Cardiology</i> , 2022, 19, 100-116.	6.1	156
38	Association Between Use of Renin-Angiotensin System Antagonists and Mortality in Patients With Heart Failure and Preserved Ejection Fraction. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 2108.	3.8	153
39	Machine Learning Methods Improve Prognostication, Identify Clinically Distinct Phenotypes, and Detect Heterogeneity in Response to Therapy in a Large Cohort of Heart Failure Patients. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	153
40	Associations with and prognostic impact of chronic kidney disease in heart failure with preserved, mid-range, and reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2017, 19, 1606-1614.	2.9	148
41	Patient selection for left ventricular assist devices. <i>European Journal of Heart Failure</i> , 2010, 12, 434-443.	2.9	145
42	Association Between Use of $\beta$ -Blockers and Outcomes in Patients With Heart Failure and Preserved Ejection Fraction. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 2008.	3.8	142
43	An ISHLT consensus document for prevention and management strategies for mechanical circulatory support infection. <i>Journal of Heart and Lung Transplantation</i> , 2017, 36, 1137-1153.	0.3	142
44	The Registry of the International Society for Heart and Lung Transplantation: Nineteenth Pediatric Heart Transplantation Report 2016; Focus Theme: Primary Diagnostic Indications for Transplant. <i>Journal of Heart and Lung Transplantation</i> , 2016, 35, 1185-1195.	0.3	138
45	Predicting survival in heart failure: validation of the MAGGIC heart failure risk score in 51 043 patients from the Swedish Heart Failure Registry. <i>European Journal of Heart Failure</i> , 2014, 16, 173-179.	2.9	134
46	Prevalence, correlates, and prognostic significance of QRS prolongation in heart failure with reduced and preserved ejection fraction. <i>European Heart Journal</i> , 2013, 34, 529-539.	1.0	132
47	European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 196-213.	2.9	131
48	The Registry of the International Society for Heart and Lung Transplantation: Eighteenth Official Pediatric Heart Transplantation Report 2015; Focus Theme: Early Graft Failure. <i>Journal of Heart and Lung Transplantation</i> , 2015, 34, 1233-1243.	0.3	130
49	The Heart Failure Association Atlas: Heart Failure Epidemiology and Management Statistics 2019. <i>European Journal of Heart Failure</i> , 2021, 23, 906-914.	2.9	130
50	Prevalence and Prognostic Implications of Longitudinal Ejection Fraction Change in Heart Failure. <i>JACC: Heart Failure</i> , 2019, 7, 306-317.	1.9	125
51	Hyperkalemia After Initiating Renin-Angiotensin System Blockade: The Stockholm Creatinine Measurements (SCREAM) Project. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	123
52	Treatments targeting inotropy. <i>European Heart Journal</i> , 2019, 40, 3626-3644.	1.0	123
53	Use of evidence-based therapy and survival in heart failure in Sweden 2003-2012. <i>European Journal of Heart Failure</i> , 2016, 18, 503-511.	2.9	121
54	The Registry of the International Society for Heart and Lung Transplantation: Seventeenth Official Pediatric Heart Transplantation Report 2014; Focus Theme: Retransplantation. <i>Journal of Heart and Lung Transplantation</i> , 2014, 33, 985-995.	0.3	120

#	ARTICLE	IF	CITATIONS
55	Association between cardiovascular vs. non-cardiovascular co-morbidities and outcomes in heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2014, 16, 992-1001.	2.9	119
56	Prognostic Significance of Resting Heart Rate and Use of $\beta$ -Blockers in Atrial Fibrillation and Sinus Rhythm in Patients With Heart Failure and Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2015, 8, 871-879.	1.6	119
57	Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial. <i>Circulation: Heart Failure</i> , 2018, 11, e004962.	1.6	117
58	Proteomic Evaluation of the Comorbidity-Inflammation Paradigm in Heart Failure With Preserved Ejection Fraction. <i>Circulation</i> , 2020, 142, 2029-2044.	1.6	117
59	Validation of peak exercise oxygen consumption and the Heart Failure Survival Score for serial risk stratification in advanced heart failure. <i>American Journal of Cardiology</i> , 2005, 95, 734-741.	0.7	116
60	Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists. <i>European Journal of Heart Failure</i> , 2018, 20, 1217-1226.	2.9	116
61	The Registry of the International Society for Heart and Lung Transplantation: Twentieth Pediatric Heart Transplantation Report 2017; Focus Theme: Allograft ischemic time. <i>Journal of Heart and Lung Transplantation</i> , 2017, 36, 1060-1069.	0.3	109
62	Inflammatory Biomarkers Predict Heart Failure Severity and Prognosis in Patients With Heart Failure With Preserved Ejection Fraction. <i>Circulation: Cardiovascular Genetics</i> , 2017, 10, .	5.1	107
63	Association Between Rheumatoid Arthritis and Risk of Ischemic and Nonischemic Heart Failure. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1275-1285.	1.2	102
64	Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care. <i>European Journal of Heart Failure</i> , 2020, 22, 2349-2369.	2.9	101
65	Health-Related Quality of Life and Mortality in Heart Failure: The Global Congestive Heart Failure Study of 23 000 Patients From 40 Countries. <i>Circulation</i> , 2021, 143, 2129-2142.	1.6	101
66	First Annual IMACS Report: A global International Society for Heart and Lung Transplantation Registry for Mechanical Circulatory Support. <i>Journal of Heart and Lung Transplantation</i> , 2016, 35, 407-412.	0.3	98
67	The Registry of the International Society for Heart and Lung Transplantation: Sixteenth Official Pediatric Lung and Heart-Lung Transplantation Report 2013; Focus Theme: Age. <i>Journal of Heart and Lung Transplantation</i> , 2013, 32, 989-997.	0.3	97
68	Association between enrolment in a heart failure quality registry and subsequent mortality: a nationwide cohort study. <i>European Journal of Heart Failure</i> , 2017, 19, 1107-1116.	2.9	94
69	Abnormalities of Potassium in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2836-2850.	1.2	94
70	Contemporary aetiology, clinical characteristics and prognosis of adults with heart failure observed in a tertiary hospital in Tanzania: the prospective Tanzania Heart Failure (TaHeF) study. <i>Heart</i> , 2014, 100, 1235-1241.	1.2	93
71	Characterization of the inflammatory-metabolic phenotype of heart failure with a preserved ejection fraction: a hypothesis to explain influence of sex on the evolution and potential treatment of the disease. <i>European Journal of Heart Failure</i> , 2020, 22, 1551-1567.	2.9	93
72	Predicting survival in ambulatory patients with severe heart failure on beta-blocker therapy. <i>American Journal of Cardiology</i> , 2003, 92, 1350-1354.	0.7	88

#	ARTICLE	IF	CITATIONS
73	Association between demographic, organizational, clinical, and socio-economic characteristics and underutilization of cardiac resynchronization therapy: results from the Swedish Heart Failure Registry. <i>European Journal of Heart Failure</i> , 2017, 19, 1270-1279.	2.9	86
74	The Registry of the International Society for Heart and Lung Transplantation: Seventeenth Official Pediatric Lung and Heart-Lung Transplantation Report 2014; Focus Theme: Retransplantation. <i>Journal of Heart and Lung Transplantation</i> , 2014, 33, 1025-1033.	0.3	84
75	Exercise training in patients with ventricular assist devices: a review of the evidence and practical advice. A position paper from the Committee on Exercise Physiology and Training and the Committee of Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2019, 21, 3-13.	2.9	84
76	Association between renin-angiotensin system antagonist use and mortality in heart failure with severe renal insufficiency: a prospective propensity score-matched cohort study. <i>European Heart Journal</i> , 2015, 36, 2318-2326.	1.0	83
77	Association Between Use of Statins and Mortality in Patients With Heart Failure and Ejection Fraction of $\geq 50\%$ . <i>Circulation: Heart Failure</i> , 2015, 8, 862-870.	1.6	83
78	Unravelling the interplay between hyperkalaemia, renin-angiotensin-aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC-HFA-EORP Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2020, 22, 1378-1389.	2.9	83
79	Interdependence of Atrial Fibrillation and Heart Failure With a Preserved Ejection Fraction Reflects a Common Underlying Atrial and Ventricular Myopathy. <i>Circulation</i> , 2020, 141, 4-6.	1.6	81
80	Sex- and age-related differences in the management and outcomes of chronic heart failure: an analysis of patients from the ESC HFA EORP Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2020, 22, 92-102.	2.9	81
81	Heart failure in women. <i>Medical Clinics of North America</i> , 2004, 88, 1321-1345.	1.1	79
82	Seattle Heart Failure and Proportional Risk Models Predict Benefit From Implantable Cardioverter-Defibrillators. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2606-2618.	1.2	79
83	The management of secondary mitral regurgitation in patients with heart failure: a joint position statement from the Heart Failure Association (HFA), European Association of Cardiovascular Imaging (EACVI), European Heart Rhythm Association (EHRA), and European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC. <i>European Heart Journal</i> , 2021, 42, 1254-1269.	1.0	78
84	New echocardiographic predictors of clinical outcome in patients presenting with heart failure and a preserved left ventricular ejection fraction: a subanalysis of the Ka (Karolinska) Ren (Rennes) Study. <i>European Journal of Heart Failure</i> , 2015, 17, 680-688.	2.9	77
85	Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction. <i>European Heart Journal</i> , 2021, 42, 3741-3752.	1.0	74
86	The Heart Failure Survival Score outperforms the peak oxygen consumption for heart transplantation selection in the era of device therapy. <i>Journal of Heart and Lung Transplantation</i> , 2011, 30, 315-325.	0.3	72
87	Registry-Based Pragmatic Trials in Heart Failure: Current Experience and Future Directions. <i>Current Heart Failure Reports</i> , 2017, 14, 59-70.	1.3	72
88	Selecting patients for heart transplantation: Comparison of the Heart Failure Survival Score (HFSS) and the Seattle Heart Failure Model (SHFM). <i>Journal of Heart and Lung Transplantation</i> , 2011, 30, 1236-1243.	0.3	71
89	The Registry of the International Society for Heart and Lung Transplantation: Eighteenth Official Pediatric Lung and Heart-Lung Transplantation Report 2015; Focus Theme: Early Graft Failure. <i>Journal of Heart and Lung Transplantation</i> , 2015, 34, 1255-1263.	0.3	71
90	Temporal Trends of De Novo Malignancy Development After Heart Transplantation. <i>Journal of the American College of Cardiology</i> , 2018, 71, 40-49.	1.2	70

#	ARTICLE	IF	CITATIONS
91	Women have better long-term prognosis than men after cardiac resynchronization therapy. <i>Europace</i> , 2012, 14, 1148-1155.	0.7	69
92	Long-term safety of intravenous cardiovascular agents in acute heart failure: results from the European Society of Cardiology Heart Failure Long-term Registry. <i>European Journal of Heart Failure</i> , 2018, 20, 332-341.	2.9	69
93	The Swedish Heart Failure Registry: a living, ongoing quality assurance and research in heart failure. <i>Uppsala Journal of Medical Sciences</i> , 2019, 124, 65-69.	0.4	68
94	Association of recipient age and causes of heart transplant mortality: Implications for personalization of post-transplant management—An analysis of the International Society for Heart and Lung Transplantation Registry. <i>Journal of Heart and Lung Transplantation</i> , 2017, 36, 407-417.	0.3	67
95	Prevalence and prognostic impact of kidney disease on heart failure patients. <i>Open Heart</i> , 2016, 3, e000324.	0.9	66
96	<scp>Heart Failure Association</scp> of the <scp>European Society of Cardiology</scp> update on sodium-glucose co-transporter 2 inhibitors in heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 1984-1986.	2.9	66
97	Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with) Tj ETQq1 1 0.784314 rgBT /Overlock 10	2.9	65
98	Identification of distinct phenotypic clusters in heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2021, 23, 973-982.	2.9	65
99	The Registry of the International Society for Heart and Lung Transplantation: Nineteenth Pediatric Lung and Heart Lung Transplantation Report—2016; Focus Theme: Primary Diagnostic Indications for Transplant. <i>Journal of Heart and Lung Transplantation</i> , 2016, 35, 1196-1205.	0.3	63
100	Incidence, Predictors, and Outcome Associations of Dyskalemia in Heart Failure With Preserved, Mid-Range, and Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2019, 7, 65-76.	1.9	62
101	Registry of the International Society for Heart and Lung Transplantation: Twentieth Pediatric Lung and Heart-Lung Transplantation Report—2017; Focus Theme: Allograft ischemic time. <i>Journal of Heart and Lung Transplantation</i> , 2017, 36, 1070-1079.	0.3	61
102	Venoarterial extracorporeal membrane oxygenation for postcardiotomy shock: Risk factors for mortality. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2018, 156, 1894-1902.e3.	0.4	61
103	Association of Candesartan vs Losartan With All-Cause Mortality in Patients With Heart Failure. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 175.	3.8	59
104	Effects of Dipeptidyl Peptidase 4 Inhibitors and Sodium-Glucose Linked coTransporter-2 Inhibitors on cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis. <i>International Journal of Cardiology</i> , 2016, 220, 595-601.	0.8	59
105	Microvascular endothelial dysfunction in heart failure with preserved ejection fraction. <i>Heart</i> , 2016, 102, 257-259.	1.2	59
106	Prognostic Models Derived in PARADIGM-HF and Validated in ATMOSPHERE and the Swedish Heart Failure Registry to Predict Mortality and Morbidity in Chronic Heart Failure. <i>JAMA Cardiology</i> , 2020, 5, 432.	3.0	59
107	Efficacy and Safety of Novel Oral Anticoagulants in Patients With Atrial Fibrillation and Heart Failure. <i>JACC: Heart Failure</i> , 2016, 4, 870-880.	1.9	58
108	Prevalence and Clinical Significance of Diabetes in Asian Versus White Patients With Heart Failure. <i>JACC: Heart Failure</i> , 2017, 5, 14-24.	1.9	57

#	ARTICLE	IF	CITATIONS
109	Repetitive use of levosimendan for treatment of chronic advanced heart failure: Clinical evidence, practical considerations, and perspectives: An expert panel consensus. <i>International Journal of Cardiology</i> , 2014, 174, 360-367.	0.8	56
110	Heart failure and dementia: survival in relation to types of heart failure and different dementia disorders. <i>European Journal of Heart Failure</i> , 2015, 17, 612-619.	2.9	55
111	Induction with anti-thymocyte globulin in heart transplantation is associated with better long-term survival compared with basiliximab. <i>Journal of Heart and Lung Transplantation</i> , 2015, 34, 1283-1291.	0.3	55
112	Gender, underutilization of cardiac resynchronization therapy, and prognostic impact of QRS prolongation and left bundle branch block in heart failure. <i>Europace</i> , 2015, 17, 424-431.	0.7	55
113	Age, prognostic impact of <sc>QRS</sc> prolongation and left bundle branch block, and utilization of cardiac resynchronization therapy: findings from 14%713 patients in the Swedish Heart Failure Registry. <i>European Journal of Heart Failure</i> , 2014, 16, 1073-1081.	2.9	54
114	Impact of Coronavirus Disease 2019 (COVID-19) Outbreak on Acute Admissions at the Emergency and Cardiology Departments Across Europe. <i>American Journal of Medicine</i> , 2021, 134, 482-489.	0.6	53
115	Left atrial strain improves estimation of filling pressures in heart failure: a simultaneous echocardiographic and invasive haemodynamic study. <i>Clinical Research in Cardiology</i> , 2019, 108, 703-715.	1.5	51
116	Excessive Weight Gain in Cardiac Transplant Recipients. <i>Journal of Heart and Lung Transplantation</i> , 2006, 25, 36-41.	0.3	50
117	Amiodarone use in patients listed for heart transplant is associated with increased 1-year post-transplant mortality. <i>Journal of Heart and Lung Transplantation</i> , 2017, 36, 202-210.	0.3	49
118	Empagliflozin Is Associated With a Lower Risk of Post-Acute Heart Failure Rehospitalization and Mortality. <i>Circulation</i> , 2019, 139, 1458-1460.	1.6	49
119	Effects of danicamtiv, a novel cardiac myosin activator, in heart failure with reduced ejection fraction: experimental data and clinical results from a phase 2a trial. <i>European Journal of Heart Failure</i> , 2020, 22, 1649-1658.	2.9	49
120	A comprehensive characterization of acute heart failure with preserved versus mildly reduced versus reduced ejection fraction—insights from the <sc>ESCâ€ˆHFA EORP</sc> Heart Failure Longâ€ˆTerm Registry. <i>European Journal of Heart Failure</i> , 2022, 24, 335-350.	2.9	49
121	Rationale and design of the Karolinskaâ€ˆRennes (KaRen) prospective study of dyssynchrony in heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2009, 11, 198-204.	2.9	47
122	Value of exercise echocardiography in heart failure with preserved ejection fraction: a substudy from the KaRen study. <i>European Heart Journal Cardiovascular Imaging</i> , 2015, 17, jev144.	0.5	47
123	Utilizing NT-proBNP for Eligibility and Enrichment in Trials in HFpEF, HFmrEF, and HFrEF. <i>JACC: Heart Failure</i> , 2018, 6, 246-256.	1.9	47
124	Association between reninâ€ˆangiotensinâ€ˆaldosterone system inhibitor use and COVIDâ€ˆ19 hospitalization and death: a 1.4 million patient nationwide registry analysis. <i>European Journal of Heart Failure</i> , 2021, 23, 476-485.	2.9	46
125	Heart failure with a preserved ejection fraction additive value of an exercise stress echocardiography. <i>European Heart Journal Cardiovascular Imaging</i> , 2012, 13, 656-665.	0.5	44
126	Prevalence of, associations with, and prognostic role of anemia in heart failure across the ejection fraction spectrum. <i>International Journal of Cardiology</i> , 2020, 298, 59-65.	0.8	44



#	ARTICLE	IF	CITATIONS
127	Comparison of Peak Exercise Oxygen Consumption and the Heart Failure Survival Score for Predicting Prognosis in Women Versus Men. <i>American Journal of Cardiology</i> , 2007, 99, 399-403.	0.7	43
128	Determinants and prognostic implications of the negative diastolic pulmonary pressure gradient in patients with pulmonary hypertension due to left heart disease. <i>European Journal of Heart Failure</i> , 2017, 19, 88-97.	2.9	43
129	Survival After Coronary Artery Bypass Grafting in Patients With Preoperative Heart Failure and Preserved vs Reduced Ejection Fraction. <i>JAMA Cardiology</i> , 2016, 1, 530.	3.0	42
130	Phenotyping heart failure patients for iron deficiency and use of intravenous iron therapy: data from the <sc>Swedish Heart Failure Registry. <i>European Journal of Heart Failure</i> , 2021, 23, 1844-1854.	2.9	42
131	Association of heart rate with mortality in sinus rhythm and atrial fibrillation in heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2019, 21, 471-479.	2.9	41
132	Triage of Patients With Moderate to Severe Heart Failure. <i>Journal of the American College of Cardiology</i> , 2014, 63, 661-671.	1.2	40
133	Baseline characteristics of patients with heart failure and preserved ejection fraction included in the Karolinska Rennes (KaRen) study. <i>Archives of Cardiovascular Diseases</i> , 2014, 107, 112-121.	0.7	40
134	Importance of combined left atrial size and estimated pulmonary pressure for clinical outcome in patients presenting with heart failure with preserved ejection fraction. <i>European Heart Journal Cardiovascular Imaging</i> , 2017, 18, 629-635.	0.5	40
135	Plasma potassium ranges associated with mortality across stages of chronic kidney disease: the Stockholm Creatinine Measurements (SCREAM) project. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1534-1541.	0.4	40
136	ST2 in heart failure with preserved and reduced ejection fraction. <i>Scandinavian Cardiovascular Journal</i> , 2019, 53, 21-27.	0.4	40
137	Nurse-led Heart Failure Clinics Are Associated With Reduced Mortality but Not Heart Failure Hospitalization. <i>Journal of the American Heart Association</i> , 2019, 8, e011737.	1.6	39
138	Association of Spironolactone Use With All-Cause Mortality in Heart Failure. <i>Circulation: Heart Failure</i> , 2013, 6, 174-183.	1.6	38
139	HFpEF and HFrEF exhibit different phenotypes as assessed by leptin and adiponectin. <i>International Journal of Cardiology</i> , 2017, 228, 709-716.	0.8	38
140	Association between renin-angiotensin system inhibitor use and mortality/morbidity in elderly patients with heart failure with reduced ejection fraction: a prospective propensity score-matched cohort study. <i>European Heart Journal</i> , 2018, 39, 4257-4265.	1.0	38
141	Hyperglycemia Induces Myocardial Dysfunction via Epigenetic Regulation of JunD. <i>Circulation Research</i> , 2020, 127, 1261-1273.	2.0	38
142	Ghrelin resistance occurs in severe heart failure and resolves after heart transplantation. <i>European Journal of Heart Failure</i> , 2009, 11, 789-794.	2.9	37
143	Association Between Use of Statins and Outcomes in Heart Failure With Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2015, 8, 252-260.	1.6	37
144	Bloodstream infections in mechanical circulatory support device recipients in the International Society of Heart and Lung Transplantation Mechanically Assisted Circulation Support Registry: Epidemiology, risk factors, and mortality. <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, 1013-1020.	0.3	37

#	ARTICLE	IF	CITATIONS
145	Stopping mineralocorticoid receptor antagonists after hyperkalaemia: trial emulation in data from routine care. <i>European Journal of Heart Failure</i> , 2021, 23, 1698-1707.	2.9	37
146	Time is prognosis™ in heart failure: time to treatment initiation as a modifiable risk factor. <i>ESC Heart Failure</i> , 2021, 8, 4444-4453.	1.4	37
147	Use of evidence-based therapy in heart failure with reduced ejection fraction across age strata. <i>European Journal of Heart Failure</i> , 2022, 24, 1047-1062.	2.9	37
148	Association between loop diuretic dose changes and outcomes in chronic heart failure: observations from the ESC-EORP Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2020, 22, 1424-1437.	2.9	36
149	Cardiac, renal, and metabolic effects of sodium-glucose cotransporter 2 inhibitors: a position paper from the European Society of Cardiology ad hoc task force on sodium-glucose cotransporter 2 inhibitors. <i>European Journal of Heart Failure</i> , 2021, 23, 1260-1275.	2.9	36
150	Cardiovascular Diseases in 1/4 30,000 Patients in the Swedish Dementia Registry. <i>Journal of Alzheimer's Disease</i> , 2015, 48, 949-958.	1.2	35
151	Sacubitril/valsartan eligibility and outcomes in the ESC-EORP-HFA Heart Failure Long-Term Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGM-HF trial, ESC guidelines, and real world. <i>European Journal of Heart Failure</i> , 2019, 21, 1383-1397.	2.9	35
152	Transthyretin amyloid deposits in lumbar spinal stenosis and assessment of signs of systemic amyloidosis. <i>Journal of Internal Medicine</i> , 2021, 289, 895-905.	2.7	35
153	Reductions in N-Terminal Pro-Brain Natriuretic Peptide Levels Are Associated With Lower Mortality and Heart Failure Hospitalization Rates in Patients With Heart Failure With Mid-Range and Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	33
154	Association between potassium level and outcomes in heart failure with reduced ejection fraction: a cohort study from the Swedish Heart Failure Registry. <i>European Journal of Heart Failure</i> , 2020, 22, 1390-1398.	2.9	33
155	Use of sodium-glucose cotransporter 2 inhibitors in patients with heart failure and type 2 diabetes mellitus: data from the Swedish Heart Failure Registry. <i>European Journal of Heart Failure</i> , 2021, 23, 1012-1022.	2.9	33
156	Association between dosing and combination use of medications and outcomes in heart failure with reduced ejection fraction: data from the Swedish Heart Failure Registry. <i>European Journal of Heart Failure</i> , 2022, 24, 871-884.	2.9	33
157	Modifications of skeletal muscle ryanodine receptor type 1 and exercise intolerance in heart failure. <i>Journal of Heart and Lung Transplantation</i> , 2013, 32, 925-929.	0.3	32
158	Associations With and Prognostic and Discriminatory Role of N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Versus Mid-range Versus Reduced Ejection Fraction. <i>Journal of Cardiac Failure</i> , 2018, 24, 365-374.	0.7	32
159	Impact of body mass index on adverse events after implantation of left ventricular assist devices: An IMACS registry analysis. <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, 1207-1217.	0.3	32
160	Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure. <i>Annals of Internal Medicine</i> , 2021, 174, 1065-1072.	2.0	32
161	COVID-19 vaccination in patients with heart failure: a position paper of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2021, 23, 1806-1818.	2.9	32
162	Patiomer for the management of hyperkalaemia in patients receiving renin-angiotensin-aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial. <i>European Journal of Heart Failure</i> , 2022, 24, 230-238.	2.9	32

#	ARTICLE	IF	CITATIONS
163	Disproportionate left atrial myopathy in heart failure with preserved ejection fraction among participants of the PROMIS-HFpEF study. <i>Scientific Reports</i> , 2021, 11, 4885.	1.6	31
164	Age-dependent differences in clinical phenotype and prognosis in heart failure with mid-range ejection compared with heart failure with reduced or preserved ejection fraction. <i>Clinical Research in Cardiology</i> , 2019, 108, 1394-1405.	1.5	30
165	Comorbidities and cause-specific outcomes in heart failure across the ejection fraction spectrum: A blueprint for clinical trial design. <i>International Journal of Cardiology</i> , 2020, 313, 76-82.	0.8	30
166	European Society of Cardiology quality indicators for the care and outcomes of adults with heart failure. Developed by the Working Group for Heart Failure Quality Indicators in collaboration with the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2022, 24, 132-142.	2.9	30
167	Right Heart Failure Following Left Ventricular Device Implantation: Natural History, Risk Factors, and Outcomes: An Analysis of the STS INTERMACS Database. <i>Circulation: Heart Failure</i> , 2022, 15, .	1.6	30
168	Signal sequence deletion and fusion to tetanus toxoid epitope augment antitumor immune responses to a human carcinoembryonic antigen (CEA) plasmid DNA vaccine in a murine test system. <i>Cancer Gene Therapy</i> , 2003, 10, 365-376.	2.2	29
169	Usefulness of Peak Exercise Oxygen Consumption and the Heart Failure Survival Score to Predict Survival in Patients >65 Years of Age With Heart Failure. <i>American Journal of Cardiology</i> , 2009, 103, 998-1002.	0.7	29
170	Screening for heart transplantation and left ventricular assist system: results from the ScREEning for advanced Heart Failure treatment (SEEâ€œHF) study. <i>European Journal of Heart Failure</i> , 2018, 20, 152-160.	2.9	29
171	Association of Coronary Microvascular Dysfunction With Heart Failure Hospitalizations and Mortality in Heart Failure With Preserved Ejection Fraction: A Follow-up in the PROMIS-HFpEF Study. <i>Journal of Cardiac Failure</i> , 2020, 26, 1016-1021.	0.7	29
172	Left atrial reservoir strain improves diagnostic accuracy of the 2016 ASE/EACVI diastolic algorithm in patients with preserved left ventricular ejection fraction: insights from the KARUM haemodynamic database. <i>European Heart Journal Cardiovascular Imaging</i> , 2022, 23, 1157-1168.	0.5	29
173	Cardiac remodelling“Part 1: From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2022, 24, 927-943.	2.9	29
174	New York Heart Association functional class, QRS duration, and survival in heart failure with reduced ejection fraction: implications for cardiac resynchronization therapy. <i>European Journal of Heart Failure</i> , 2017, 19, 366-376.	2.9	28
175	Cardiomyopathy, oxidative stress and impaired contractility in a rheumatoid arthritis mouse model. <i>Heart</i> , 2018, 104, 2026-2034.	1.2	28
176	Patient reported outcome in HFpEF: Sex-specific differences in quality of life and association with outcome. <i>International Journal of Cardiology</i> , 2018, 267, 128-132.	0.8	28
177	Myeloperoxidase and related biomarkers are suggestive footprints of endothelial microvascular inflammation in HFpEF patients. <i>ESC Heart Failure</i> , 2020, 7, 1534-1546.	1.4	28
178	Cardiac implantable electronic devices with a defibrillator component and all-cause mortality in left ventricular assist device carriers: results from the PCHFâ€œVAD registry. <i>European Journal of Heart Failure</i> , 2019, 21, 1129-1141.	2.9	27
179	Antithrombotic therapy and major adverse limb events in patients with chronic lower extremity arterial disease: systematic review and meta-analysis from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy in Collaboration with the European Society of Cardiology Working Group on Aorta and Peripheral Vascular Diseases. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 86-93.	1.4	27
180	Comparison Across Races of Peak Oxygen Consumption and Heart Failure Survival Score for Selection for Cardiac Transplantation. <i>American Journal of Cardiology</i> , 2010, 105, 1439-1444.	0.7	26

#	ARTICLE	IF	CITATIONS
181	Heart, lung, and vascular registries: Evolving goals, successful approaches, and ongoing innovation. <i>Journal of Heart and Lung Transplantation</i> , 2016, 35, 1149-1157.	0.3	26
182	A real-world cohort study on the quality of potassium and creatinine monitoring during initiation of mineralocorticoid receptor antagonists in patients with heart failure. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , 2018, 4, 267-273.	1.8	26
183	Lower socioeconomic status predicts higher mortality and morbidity in patients with heart failure. <i>Heart</i> , 2021, 107, 229-236.	1.2	26
184	Heart failure in COVID-19: the multicentre, multinational PCHF-COVICAV registry. <i>ESC Heart Failure</i> , 2021, 8, 4955-4967.	1.4	26
185	An update on global epidemiology in heart failure. <i>European Heart Journal</i> , 2022, 43, 3005-3007.	1.0	26
186	Heart Failure With "Mid-Range" Ejection Fraction: New Opportunities. <i>Journal of Cardiac Failure</i> , 2016, 22, 769-771.	0.7	25
187	Comparison of the Chronic Kidney Disease Epidemiology Collaboration, the Modification of Diet in Renal Disease study and the Cockcroft-Gault equation in patients with heart failure. <i>Open Heart</i> , 2017, 4, e000568.	0.9	25
188	HFpEF and HFrEF Display Different Phenotypes as Assessed by IGF-1 and IGFBP-1. <i>Journal of Cardiac Failure</i> , 2017, 23, 293-303.	0.7	25
189	Reasons for and consequences of oral anticoagulant underuse in atrial fibrillation with heart failure. <i>Heart</i> , 2018, 104, 1093-1100.	1.2	25
190	Focusing on Referral Rather than Selection for Advanced Heart Failure Therapies. <i>Cardiac Failure Review</i> , 2019, 5, 24-26.	1.2	25
191	Prevalence and prognostic implications of anaemia and iron deficiency in Tanzanian patients with heart failure. <i>Heart</i> , 2015, 101, 592-599.	1.2	23
192	Ivabradine in Heart Failure. <i>Circulation: Heart Failure</i> , 2017, 10, .	1.6	23
193	Impaired left atrial dynamics and its improvement by guided physical activity reveal left atrial strain as a novel early indicator of reversible cardiac dysfunction in rheumatoid arthritis. <i>European Journal of Preventive Cardiology</i> , 2018, 25, 1106-1108.	0.8	23
194	Type 2 diabetes increases the long-term risk of heart failure and mortality in patients with atrial fibrillation. <i>European Journal of Heart Failure</i> , 2020, 22, 113-125.	2.9	23
195	Is heart failure misdiagnosed in hospitalized patients with preserved ejection fraction? From the European Society of Cardiology Heart Failure Association EURObservational Research Programme Heart Failure Long-Term Registry. <i>ESC Heart Failure</i> , 2020, 7, 2098-2112.	1.4	23
196	Cardiovascular effects of non-insulin glucose-lowering agents: a comprehensive review of trial evidence and potential cardioprotective mechanisms. <i>Cardiovascular Research</i> , 2022, 118, 2231-2252.	1.8	23
197	Non-cardiology vs. cardiology care of patients with heart failure and reduced ejection fraction is associated with lower use of guideline-based care and higher mortality: Observations from The Swedish Heart Failure Registry. <i>International Journal of Cardiology</i> , 2021, 343, 63-72.	0.8	23
198	Patient profile and outcomes associated with follow-up in specialty vs. primary care in heart failure. <i>ESC Heart Failure</i> , 2022, 9, 822-833.	1.4	23

#	ARTICLE	IF	CITATIONS
199	Subtypes of atrial fibrillation with concomitant valvular heart disease derived from electronic health records: phenotypes, population prevalence, trends and prognosis. <i>Europace</i> , 2019, 21, 1776-1784.	0.7	22
200	Therapeutic inertia in the pharmacological management of heart failure with reduced ejection fraction. <i>ESC Heart Failure</i> , 2022, 9, 2063-2069.	1.4	22
201	Cardiac remodelling—Part 2: Clinical, imaging and laboratory findings. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2022, 24, 944-958.	2.9	22
202	Peak VO <sub>2</sub> in elderly patients with heart failure. <i>International Journal of Cardiology</i> , 2008, 125, 166-171.	0.8	21
203	Efficacy and safety of glucagon-like peptide-1 agonists on macrovascular and microvascular events in type 2 diabetes mellitus: A meta-analysis. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2017, 27, 1081-1088.	1.1	21
204	Trends in the use of mechanical circulatory support as a bridge to heart transplantation across different age groups. <i>International Journal of Cardiology</i> , 2017, 231, 225-227.	0.8	21
205	Acceleration of kidney function decline after incident hospitalization with cardiovascular disease: the Stockholm <i>creatinine</i> Measurements ( <i>SCREAM</i> ) project. <i>European Journal of Heart Failure</i> , 2020, 22, 1790-1799.	2.9	21
206	Growth hormone resistance in severe heart failure resolves after cardiac transplantation. <i>European Journal of Heart Failure</i> , 2009, 11, 525-528.	2.9	20
207	Effect of Heart Rate and Use of Beta Blockers on Mortality After Heart Transplantation. <i>American Journal of Cardiology</i> , 2016, 118, 1916-1921.	0.7	20
208	Incidence of, Associations With and Prognostic Impact of Worsening Renal Function in Heart Failure With Different Ejection Fraction Categories. <i>American Journal of Cardiology</i> , 2019, 124, 1575-1583.	0.7	20
209	Generalizability of HFA-PEFF and H2FPEF Diagnostic Algorithms and Associations With Heart Failure Indices and Proteomic Biomarkers: Insights From PROMIS-HFpEF. <i>Journal of Cardiac Failure</i> , 2021, 27, 756-765.	0.7	20
210	Comparison of Prognostic Usefulness of Serum Insulin-Like Growth Factor-Binding Protein 7 in Patients With Heart Failure and Preserved Versus Reduced Left Ventricular Ejection Fraction. <i>American Journal of Cardiology</i> , 2018, 121, 1558-1566.	0.7	19
211	Time-dependent prognostic effects of recipient and donor age in adult heart transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2019, 38, 174-183.	0.3	19
212	VA-ECMO Support in Nonsurgical Patients With Refractory Cardiogenic Shock: Pre-implant Outcome Predictors. <i>Artificial Organs</i> , 2019, 43, 132-141.	1.0	19
213	Implementation of sacubitril/valsartan in Sweden: clinical characteristics, titration patterns, and determinants. <i>ESC Heart Failure</i> , 2020, 7, 3633-3643.	1.4	19
214	Eligibility for Dapagliflozin and Empagliflozin in a Real-world Heart Failure Population. <i>Journal of Cardiac Failure</i> , 2022, 28, 1050-1062.	0.7	19
215	Extracorporeal membrane oxygenation as a rescue of intractable ventricular fibrillation and bridge to heart transplantation. <i>European Journal of Heart Failure</i> , 2010, 12, 301-304.	2.9	18
216	Derived and Displayed Power Consumption, Flow, and Pulsatility Over a Range of HeartMate II Left Ventricular Assist Device Settings. <i>ASAIO Journal</i> , 2012, 58, 183-190.	0.9	18

#	ARTICLE	IF	CITATIONS
217	Utility of the Seattle Heart Failure Model in patients with cardiac resynchronization therapy and implantable cardioverter defibrillator referred for heart transplantation. <i>American Heart Journal</i> , 2014, 168, 325-331.	1.2	18
218	Efficacy and safety of prolonged dual antiplatelet therapy: a meta-analysis of 15 randomized trials enrolling 85 265 patients. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2016, 2, 218-228.	1.4	18
219	Predicting Risk in Patients Hospitalized for Acute Decompensated Heart Failure and Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2017, 10, .	1.6	18
220	Effect of expanding evidence and evolving clinical guidelines on the prevalence of indication for cardiac resynchronization therapy in patients with heart failure. <i>European Journal of Heart Failure</i> , 2018, 20, 769-777.	2.9	18
221	Prognostic impact of Framingham heart failure criteria in heart failure with preserved ejection fraction. <i>ESC Heart Failure</i> , 2019, 6, 830-839.	1.4	18
222	Clinical and research implications of serum versus plasma potassium measurements. <i>European Journal of Heart Failure</i> , 2019, 21, 536-537.	2.9	18
223	Recurrent hyperkalaemia management and use of renin-angiotensin-aldosterone system inhibitors: a European multi-national targeted chart review. <i>CKJ: Clinical Kidney Journal</i> , 2020, 13, 714-719.	1.4	18
224	Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care. <i>Europace</i> , 2021, 23, 1324-1342.	0.7	18
225	Serum uric acid and outcomes in patients with chronic heart failure through the whole spectrum of ejection fraction phenotypes: Analysis of the ESC-EORP Heart Failure Long-Term (HF LT) Registry. <i>European Journal of Internal Medicine</i> , 2021, 89, 65-75.	1.0	18
226	Myocardial recovery in peri-partum cardiomyopathy after continuous flow left ventricular assist device. <i>Journal of Cardiothoracic Surgery</i> , 2011, 6, 150.	0.4	17
227	Awareness of indications for device therapy among a broad range of physicians: a survey study. <i>Europace</i> , 2014, 16, 1580-1586.	0.7	17
228	Adaptive cardiovascular hormones in a spectrum of heart failure phenotypes. <i>International Journal of Cardiology</i> , 2015, 189, 6-11.	0.8	17
229	Is ejection fraction in heart failure a limitation or an opportunity?. <i>European Journal of Heart Failure</i> , 2018, 20, 431-432.	2.9	17
230	Randomized trial of a left ventricular assist device as destination therapy versus guideline-directed medical therapy in patients with advanced heart failure. Rationale and design of the SWEdish evaluation of left Ventricular Assist Device (SweVAD) trial. <i>European Journal of Heart Failure</i> , 2020, 22, 739-750.	2.9	17
231	Association Between $\beta$ -Blockers and Outcomes in Heart Failure With Preserved Ejection Fraction: Current Insights From the SwedeHF Registry. <i>Journal of Cardiac Failure</i> , 2021, 27, 1165-1174.	0.7	17
232	Acute coronary syndrome in octogenarians: association between percutaneous coronary intervention and long-term mortality. <i>Clinical Interventions in Aging</i> , 2015, 10, 1547.	1.3	16
233	Copeptin in patients with heart failure and preserved ejection fraction: a report from the prospective KaRen-study. <i>Open Heart</i> , 2015, 2, e000260.	0.9	16
234	Biomarker Correlates of Coronary Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction. <i>Circulation</i> , 2019, 140, 1359-1361.	1.6	16

#	ARTICLE	IF	CITATIONS
235	Congestion and Diuretic Resistance in Acute or Worsening Heart Failure. <i>Cardiac Failure Review</i> , 2020, 6, e25.	1.2	16
236	Transient versus persistent improved ejection fraction in non-ischaemic dilated cardiomyopathy. <i>European Journal of Heart Failure</i> , 2022, 24, 1171-1179.	2.9	16
237	Ethnic differences in the association of QRS duration with ejection fraction and outcome in heart failure. <i>Heart</i> , 2016, 102, 1464-1471.	1.2	15
238	Induction immunosuppression strategies and long-term outcomes after heart transplantation. <i>Clinical Transplantation</i> , 2020, 34, e13871.	0.8	15
239	Risk stratification with echocardiographic biomarkers in heart failure with preserved ejection fraction: the media echo score. <i>ESC Heart Failure</i> , 2021, 8, 1827-1839.	1.4	15
240	Left ventricular ejection fraction as the primary heart failure phenotyping parameter. <i>European Journal of Heart Failure</i> , 2022, 24, 1158-1161.	2.9	15
241	A functional genetic approach suggests a novel interaction between the human immunodeficiency virus type 1 (HIV-1) Tat protein and HIV-1 TAR RNA in vivo. <i>Journal of General Virology</i> , 2003, 84, 603-606.	1.3	14
242	Increases in Cardiac Output and Oxygen Consumption During Enhanced External Counterpulsation. <i>Heart Lung and Circulation</i> , 2016, 25, 1133-1136.	0.2	14
243	Association Between Use of Long-Acting Nitrates and Outcomes in Heart Failure With Preserved Ejection Fraction. <i>CLINICAL PERSPECTIVE. Circulation: Heart Failure</i> , 2017, 10, e003534.	1.6	14
244	Is hyperkalaemia in heart failure a risk factor or a risk marker? Implications for renin-angiotensin-aldosterone system inhibitor use. <i>European Journal of Heart Failure</i> , 2018, 20, 931-932.	2.9	14
245	Different relationships between pulse pressure and mortality in heart failure with reduced, mid-range and preserved ejection fraction. <i>International Journal of Cardiology</i> , 2018, 254, 203-209.	0.8	14
246	N-terminal pro-B-type natriuretic peptide in chronic heart failure: The impact of sex across the ejection fraction spectrum. <i>International Journal of Cardiology</i> , 2019, 287, 66-72.	0.8	14
247	Empagliflozin in Heart Failure With Predicted Preserved Versus Reduced Ejection Fraction: Data From the EMPA-REG OUTCOME Trial. <i>Journal of Cardiac Failure</i> , 2021, 27, 888-895.	0.7	14
248	Atrial disease and heart failure: the common soil hypothesis proposed by the Heart Failure Association of the European Society of Cardiology. <i>European Heart Journal</i> , 2022, 43, 863-867.	1.0	14
249	Leptin resistance after heart transplantation. <i>European Journal of Heart Failure</i> , 2010, 12, 516-520.	2.9	13
250	Assessment of a University of California, Los Angeles 4-Variable Risk Score for Advanced Heart Failure. <i>Journal of the American Heart Association</i> , 2014, 3, e000998.	1.6	13
251	Planned repetitive use of levosimendan for heart failure in cardiology and internal medicine in Sweden. <i>International Journal of Cardiology</i> , 2014, 175, 55-61.	0.8	13
252	Heart failure in Tanzania and Sweden: Comparative characterization and prognosis in the Tanzania Heart Failure (TaHeF) study and the Swedish Heart Failure Registry (SwedeHF). <i>International Journal of Cardiology</i> , 2016, 220, 750-758.	0.8	13

#	ARTICLE	IF	CITATIONS
253	A comprehensive assessment of the association between anemia, clinical covariates and outcomes in a population-wide heart failure registry. <i>International Journal of Cardiology</i> , 2016, 211, 124-131.	0.8	13
254	Non-insulin antihyperglycaemic drugs and heart failure: an overview of current evidence from randomized controlled trials. <i>ESC Heart Failure</i> , 2020, 7, 3438-3451.	1.4	13
255	A registry-based algorithm to predict ejection fraction in patients with heart failure. <i>ESC Heart Failure</i> , 2020, 7, 2388-2397.	1.4	13
256	Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan. <i>Circulation: Heart Failure</i> , 2021, 14, e008052.	1.6	13
257	Predictors of long-term outcome in heart failure with preserved ejection fraction: a follow-up from the <sc>KaRen</sc> study. <i>ESC Heart Failure</i> , 2021, 8, 4243-4254.	1.4	13
258	Biomarkers for the prediction of heart failure and cardiovascular events in patients with type 2 diabetes: a position statement from the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2022, 24, 1162-1170.	2.9	13
259	Haemodynamic effects of levosimendan in advanced but stable chronic heart failure. <i>ESC Heart Failure</i> , 2018, 5, 302-308.	1.4	12
260	Association Between $\beta$ -Blocker Use and Mortality/Morbidity in Patients With Heart Failure With Reduced, Midrange, and Preserved Ejection Fraction and Advanced Chronic Kidney Disease. <i>Circulation: Heart Failure</i> , 2020, 13, e007180.	1.6	12
261	Data standards for heart failure: the European Unified Registries for Heart Care Evaluation and Randomized Trials (EuroHeart). <i>European Heart Journal</i> , 2022, 43, 2185-2195.	1.0	12
262	Optimizing outcomes after heart transplantation. <i>European Journal of Heart Failure</i> , 2018, 20, 395-397.	2.9	11
263	Heart failure and the risk of acute kidney injury in relation to ejection fraction in patients undergoing coronary artery bypass grafting. <i>International Journal of Cardiology</i> , 2019, 274, 66-70.	0.8	11
264	Validation of non-invasive ramp testing for HeartMate 3. <i>ESC Heart Failure</i> , 2020, 7, 663-672.	1.4	11
265	Circulating neuregulin1 $\beta$ in heart failure with preserved and reduced left ventricular ejection fraction. <i>ESC Heart Failure</i> , 2020, 7, 445-455.	1.4	11
266	Mechanistic and Therapeutic Implications of Extracellular Vesicles as a Potential Link Between Covid-19 and Cardiovascular Disease Manifestations. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 640723.	1.8	11
267	Generalizability of randomized controlled trials in heart failure with reduced ejection fraction. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , 2022, 8, 761-769.	1.8	11
268	Management of Left Ventricular Rupture After Myocardial Infarction Solely With ECMO. <i>Circulation: Heart Failure</i> , 2012, 5, e65-7.	1.6	10
269	Effects of Spinal Cord Stimulation on Cardiac Sympathetic Nerve Activity in Patients with Heart Failure. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2017, 40, 504-513.	0.5	10
270	Streamlining cardiovascular clinical trials to improve efficiency and generalisability. <i>Heart</i> , 2017, 103, 1156-1162.	1.2	10



#	ARTICLE	IF	CITATIONS
271	The Inescapable Heterogeneity of Heart Failure. <i>Journal of Cardiac Failure</i> , 2017, 23, 351-352.	0.7	10
272	Importance of structural heart disease and diastolic dysfunction in heart failure with preserved ejection fraction assessed according to the ESC guidelines - A substudy in the Ka (Karolinska) Ren (Rennes) study. <i>International Journal of Cardiology</i> , 2019, 274, 202-207.	0.8	10
273	Hyperkalemia in heart failure patients in Spain and its impact on guidelines and recommendations: ESC-EORP-HFA Heart Failure Long-Term Registry. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2020, 73, 313-323.	0.4	10
274	Diagnostic utility of right atrial reservoir strain to identify elevated right atrial pressure in heart failure. <i>International Journal of Cardiology</i> , 2021, 324, 227-232.	0.8	10
275	Cardiac resynchronization therapy with or without defibrillator in patients with heart failure. <i>Europace</i> , 2022, 24, 48-57.	0.7	10
276	Improved survival of left ventricular assist device carriers in Europe according to implantation eras: results from the PCHF&VAD registry. <i>European Journal of Heart Failure</i> , 2022, 24, 1305-1315.	2.9	10
277	Predictors of primary prevention implantable cardioverter-defibrillator use in heart failure with reduced ejection fraction: impact of the predicted risk of sudden cardiac death and all-cause mortality. <i>European Journal of Heart Failure</i> , 2022, 24, 1212-1222.	2.9	10
278	Risk scores and biomarkers in heart failure: A journey to predictive accuracy and clinical utility. <i>Journal of Heart and Lung Transplantation</i> , 2016, 35, 711-713.	0.3	9
279	Copeptin in Heart Failure, Post-Left Ventricular Assist Device and Post-Heart Transplantation. <i>Heart Lung and Circulation</i> , 2017, 26, 143-149.	0.2	9
280	Accuracy of echocardiographic estimates of pulmonary artery pressures in pulmonary hypertension: insights from the KARUM hemodynamic database. <i>International Journal of Cardiovascular Imaging</i> , 2021, 37, 2637-2645.	0.7	9
281	Heart Failure with Mid-range Ejection Fraction: Lessons from CHARM. <i>Cardiac Failure Review</i> , 2018, 4, 70.	1.2	9
282	Digoxin use in contemporary heart failure with reduced ejection fraction: an analysis from the Swedish Heart Failure Registry. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 756-767.	1.4	9
283	Catheter ablation for patients with atrial fibrillation and heart failure: insights from the Swedish Heart Failure Registry. <i>European Journal of Heart Failure</i> , 2022, 24, 1636-1646.	2.9	9
284	Heart failure: a weak link in CHA <sub>2</sub> DS <sub>2</sub> -VASc. <i>ESC Heart Failure</i> , 2018, 5, 231-239.	1.4	8
285	Complexities of the Global Heart Failure Epidemic. <i>Journal of Cardiac Failure</i> , 2018, 24, 813-814.	0.7	8
286	Limited value of NT-proBNP as a prognostic marker of all-cause mortality in patients with heart failure with preserved and mid-range ejection fraction in primary care: A report from the swedish heart failure register. <i>Scandinavian Journal of Primary Health Care</i> , 2019, 37, 434-443.	0.6	8
287	The additive value of echocardiographic pulmonary to left atrial global strain ratio in the diagnosis of pulmonary hypertension. <i>International Journal of Cardiology</i> , 2019, 292, 205-210.	0.8	8
288	Improving long-term outcomes with left ventricular assist devices: referral, selection, experience, and technology. <i>European Journal of Heart Failure</i> , 2019, 21, 101-102.	2.9	8

#	ARTICLE	IF	CITATIONS
289	Comparative associations between angiotensin converting enzyme inhibitors, angiotensin receptor blockers and their combination, and outcomes in patients with heart failure and reduced ejection fraction. <i>International Journal of Cardiology</i> , 2015, 199, 415-423.	0.8	7
290	Negotiating renal dysfunction when treating patients with heart failure. <i>Expert Review of Cardiovascular Therapy</i> , 2018, 16, 113-122.	0.6	7
291	Association Between High-Dose Spironolactone and Decongestion in Patients with Acute Heart Failure: An Observational Retrospective Study. <i>American Journal of Cardiovascular Drugs</i> , 2018, 18, 415-422.	1.0	7
292	Doppler estimates of pulmonary vascular resistance to phenotype pulmonary hypertension in heart failure. <i>International Journal of Cardiovascular Imaging</i> , 2019, 35, 1465-1472.	0.7	7
293	Heart Failure in Patients Undergoing Elective and Emergency Noncardiac Surgery: Still a Poorly Addressed Risk Factor. <i>Journal of Cardiac Failure</i> , 2020, 26, 1034-1042.	0.7	7
294	Management of heart failure with reduced ejection fraction in Europe: design of the ARIADNE registry. <i>ESC Heart Failure</i> , 2020, 7, 727-736.	1.4	7
295	Implementation science and potential for screening in heart failure. <i>European Heart Journal</i> , 2022, 43, 413-415.	1.0	7
296	Identifying patients for advanced heart failure therapy by screening patients with cardiac resynchronization therapy or implantable cardioverter-defibrillator: A pilot study. <i>Journal of Heart and Lung Transplantation</i> , 2013, 32, 651-654.	0.3	6
297	Peripheral Extracorporeal Membrane Oxygenation as Short-Term Right Ventricular Support After HeartWare Left Ventricular Assist Device Implantation. <i>ASAIO Journal</i> , 2013, 59, 523-525.	0.9	6
298	HeartWare left ventricular assist device thrombosis in aspirin non-responder. <i>Asian Cardiovascular and Thoracic Annals</i> , 2014, 22, 203-204.	0.2	6
299	Biomarkers in advanced heart failure—pathophysiology leading to clinical use?. <i>Journal of Heart and Lung Transplantation</i> , 2014, 33, 1213-1214.	0.3	6
300	Cardiac resynchronization therapy: results, challenges and perspectives for the future. <i>Scandinavian Cardiovascular Journal</i> , 2016, 50, 282-292.	0.4	6
301	The prognostic significance of atrial fibrillation in heart failure with preserved ejection function: insights from KaRen, a prospective and multicenter study. <i>Heart and Vessels</i> , 2017, 32, 735-749.	0.5	6
302	Complex relationships between comorbidity, outcomes, and treatment effect in heart failure. <i>European Journal of Heart Failure</i> , 2018, 20, 511-513.	2.9	6
303	Echocardiographic Biventricular Coupling Index to Predict Precapillary Pulmonary Hypertension. <i>Journal of the American Society of Echocardiography</i> , 2022, 35, 715-726.	1.2	6
304	Change in blood pressure during hospitalisation for acute heart failure predicts mortality. <i>Scandinavian Cardiovascular Journal</i> , 2010, 44, 325-330.	0.4	5
305	Acylation of ghrelin is increased in heart failure and decreases post heart transplantation. <i>Scandinavian Cardiovascular Journal</i> , 2014, 48, 343-348.	0.4	5
306	Unmet Needs and Prioritization in Heart Failure. <i>Journal of Cardiac Failure</i> , 2016, 22, 587-588.	0.7	5

#	ARTICLE	IF	CITATIONS
307	Spinal cord stimulation in heart failure: effect on disease-associated biomarkers. <i>European Journal of Heart Failure</i> , 2017, 19, 283-286.	2.9	5
308	Pre-Implant Outcome Predictors in Patients With Refractory Cardiogenic Shock Supported With VA-ECMO. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2094-2096.	1.2	5
309	The year in cardiology 2017: heart failure. <i>European Heart Journal</i> , 2018, 39, 832-839.	1.0	5
310	Controller and battery changes due to technical problems related to the HVAD® left ventricular assist device - a single center experience. <i>Journal of Cardiothoracic Surgery</i> , 2018, 13, 74.	0.4	5
311	Continuous-flow LVADs in the Nordic countries: complications and mortality and its predictors. <i>Scandinavian Cardiovascular Journal</i> , 2019, 53, 14-20.	0.4	5
312	Do Patients With Acute Heart Failure and Preserved Ejection Fraction Have Heart Failure at Follow-Up: Implications of the Framingham Criteria. <i>Journal of Cardiac Failure</i> , 2020, 26, 673-684.	0.7	5
313	The Differential Impact of the Left Atrial Pressure Components on Pulmonary Arterial Compliance-Resistance Relationship in Heart Failure. <i>Journal of Cardiac Failure</i> , 2021, 27, 277-285.	0.7	5
314	Electrostatic Discharge Causing Pump Shutdown in HeartMate 3. <i>JACC: Case Reports</i> , 2021, 3, 459-463.	0.3	5
315	Eligibility of patients with heart failure with preserved ejection fraction for sacubitril/valsartan according to the PARAGON-HF trial. <i>ESC Heart Failure</i> , 2022, 9, 164-177.	1.4	5
316	Apparent Treatment-Resistant Hypertension Across the Spectrum of Heart Failure Phenotypes in the Swedish HF Registry. <i>JACC: Heart Failure</i> , 2022, 10, 380-392.	1.9	5
317	From mid-range to mildly reduced ejection fraction heart failure: A call to treat. <i>European Journal of Internal Medicine</i> , 2022, 103, 29-35.	1.0	5
318	Changes in natriuretic peptides after acute hospital presentation for heart failure with preserved ejection fraction: A feasible surrogate trial endpoint? A report from the prospective Karen study. <i>International Journal of Cardiology</i> , 2017, 226, 65-70.	0.8	4
319	Association Between Mineralocorticoid Receptor Antagonist Use and Outcome in Myocardial Infarction Patients With Heart Failure. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	4
320	Feasibility and accuracy of tricuspid annular displacement assessed by speckle tracking echocardiography and Doppler tissue imaging. <i>Echocardiography</i> , 2019, 36, 2004-2009.	0.3	4
321	Increasing Complexity of Heart Failure Therapy Requires Earlier and More Frequent Referral. <i>Journal of Cardiac Failure</i> , 2019, 25, 317-318.	0.7	4
322	Modeling defibrillation benefit for survival among cardiac resynchronization therapy defibrillator recipients. <i>American Heart Journal</i> , 2020, 222, 93-104.	1.2	4
323	Use of loop diuretics in chronic heart failure: do we adhere to the Hippocratic principle "do no harm"? <i>European Journal of Heart Failure</i> , 2021, 23, 1068-1075.	2.9	4
324	Biomarker changes as surrogate endpoints in early-phase trials in heart failure with reduced ejection fraction. <i>ESC Heart Failure</i> , 2022, 9, 2107-2118.	1.4	4

#	ARTICLE	IF	CITATIONS
325	Individual rights and autonomy in clinical research. <i>European Journal of Heart Failure</i> , 2010, 12, 311-312.	2.9	3
326	Aldosterone Inhibition in Patients With Heart Failure With Preserved Ejection Fraction. <i>JAMA - Journal of the American Medical Association</i> , 2013, 310, 205.	3.8	3
327	Optimal Eligibility Criteria for Trials in Heart Failure With Preserved Ejection Fraction. <i>Journal of Cardiac Failure</i> , 2017, 23, 528-529.	0.7	3
328	Digoxin: beneficial or harmful?. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2017, 3, 127-128.	1.4	3
329	Rituximab Induction and Risk of Cardiac Allograft Vasculopathy, Rejection and Death. <i>Journal of Heart and Lung Transplantation</i> , 2017, 36, S88.	0.3	3
330	Continuousâ€flow mechanical circulatory support is not associated with early graft failure: An analysis of the International Society for Heart and Lung Transplantation registry. <i>Clinical Transplantation</i> , 2019, 33, e13752.	0.8	3
331	Critical appraisal of the instantaneous endâ€diastolic pulmonary arterial wedge pressures. <i>ESC Heart Failure</i> , 2020, 7, 4247-4255.	1.4	3
332	Pragmatic approaches to the next generation of clinical trials in heart failure. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 282-283.	1.4	3
333	Optimizing diastolic pressure gradient assessment. <i>Clinical Research in Cardiology</i> , 2020, 109, 1411-1422.	1.5	3
334	Baseline characteristics of 547 new onset heart failure patients in the PREFERS heart failure study. <i>ESC Heart Failure</i> , 2022, 9, 2125-2138.	1.4	3
335	Primary murine cells as a model for HIV-1 infection. <i>Aids</i> , 2004, 18, 1067-1069.	1.0	2
336	Emergency Parallel Mechanical Circulatory Support for Ventricular Fibrillation. <i>Circulation: Heart Failure</i> , 2014, 7, 229-230.	1.6	2
337	Incretin-based therapy for type 2 diabetes: A real class effect?. <i>International Journal of Cardiology</i> , 2017, 227, 141-142.	0.8	2
338	Heart transplantation outcomes for rheumatic heart disease: Analysis of international registry data. <i>Clinical Transplantation</i> , 2018, 32, e13439.	0.8	2
339	Early and Late Right Heart Failure Following LVAD Implantation: Epidemiology, Natural History and Outcomes. An Analysis of the STS INTERMACS Database. <i>Journal of Heart and Lung Transplantation</i> , 2019, 38, S20.	0.3	2
340	Diagnosis of Heart Failure. <i>Cardiovascular Medicine</i> , 2019, , 83-101.	0.0	2
341	Atrial fibrillation in heart failure with preserved ejection fraction: a risk marker, risk factor or confounder?. <i>Heart</i> , 2020, 106, 1949-1949.	1.2	2
342	New trial evidence and guidelines on heart failure: news from the European Society of Cardiology Congress 2021. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, e89-e90.	1.4	2

#	ARTICLE	IF	CITATIONS
343	Survival Probability and Survival Benefit Associated With Primary Prevention Implantable Cardioverter-Defibrillator Generator Changes. <i>Journal of the American Heart Association</i> , 2022, 11, .	1.6	2
344	Ethics in human research: when is clinical practice research?. <i>European Journal of Heart Failure</i> , 2009, 11, 531-532.	2.9	1
345	What is the relationship between cardiac and peripheral ghrelin production? Reply. <i>European Journal of Heart Failure</i> , 2009, 11, 1111-1111.	2.9	1
346	What are the true prognostic differences between heart failure with preserved and reduced ejection fraction?. <i>European Journal of Heart Failure</i> , 2010, 12, 98-98.	2.9	1
347	Cost-Effectiveness of Sacubitril/Valsartan in Heart Failure with Reduced Ejection Fraction in Sweden. <i>Value in Health</i> , 2016, 19, A650-A651.	0.1	1
348	Arterial-ventricular and interventricular interaction in isolated post-capillary and combined pulmonary hypertension in severe mitral stenosis. <i>European Journal of Applied Physiology</i> , 2016, 116, 1545-1554.	1.2	1
349	Ticagrelor versus prasugrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention: An unresolved issue. <i>International Journal of Cardiology</i> , 2017, 249, 77-78.	0.8	1
350	If it ain't broken, don't fix it (but if it is, make sure you know): aortic valve interventions during left ventricular assist device implantation. <i>European Journal of Heart Failure</i> , 2020, 22, 1888-1890.	2.9	1
351	Acknowledging the complex puzzle that links heart failure hospitalizations to outcomes. Letter regarding the article "Readmission and death in patients admitted with new-onset versus worsening of chronic heart failure: insights from a nationwide cohort"™. <i>European Journal of Heart Failure</i> , 2021, 23, 683-683.	2.9	1
352	A case report about successful treatment of refractory ventricular tachycardia with ablation under prolonged haemodynamic support with extracorporeal membrane oxygenation. <i>European Heart Journal - Case Reports</i> , 2021, 5, ytab084.	0.3	1
353	Accuracy and diagnostic performance of doppler echocardiography to estimate mean pulmonary artery pressure in heart failure. <i>Echocardiography</i> , 2021, 38, 1624-1631.	0.3	1
354	Up-titrating angiotensin-converting enzyme inhibitors in heart failure: evidence and challenges. <i>European Journal of Heart Failure</i> , 2018, 20, 370-372.	2.9	1
355	The continued value of risk scores in advanced heart failure. <i>Kardiologia Polska</i> , 2018, 76, 1299-1300.	0.3	1
356	ACE inhibitors in African Americans with hypertension associated with worse outcomes as compared to other antihypertensives. <i>Evidence-Based Medicine</i> , 2016, 21, 33-34.	0.6	0
357	249Long-term outcome in myocardial infarction patients with heart failure treated with aldosterone receptor antagonist in relation to ejection fraction and kidney function. <i>European Heart Journal</i> , 2017, 38, .	1.0	0
358	P2300Importance of structural heart disease and diastolic dysfunction in heart failure with preserved ejection fraction assessed according to the ESC guidelines. <i>European Heart Journal</i> , 2017, 38, .	1.0	0
359	Anaemia and iron deficiency in heart failure: epidemiological gaps, diagnostic challenges and therapeutic barriers in sub-Saharan Africa. <i>Cardiovascular Journal of Africa</i> , 2017, 28, 331-337.	0.2	0
360	Running Out of Success in HF Therapy ?. <i>Journal of Cardiac Failure</i> , 2018, 24, 63-64.	0.7	0

#	ARTICLE	IF	CITATIONS
361	Reply. JACC: Heart Failure, 2019, 7, 533-534.	1.9	0
362	The GUIDEâ€” heart failure risk prediction model: another fish in the sea?. European Journal of Heart Failure, 2019, 21, 779-780.	2.9	0
363	PARAGON-HF - considerations for potential use of sacubitril-valsartan in real-world heart failure with mildly reduced ejection fraction. Journal of Cardiac Failure, 2019, 25, 1012-1013.	0.7	0
364	Iron deficiency in heart failure. International Journal of Cardiology, 2020, 299, 207.	0.8	0
365	Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction: Treating Resistance, Impedance, and Compliance. Journal of Cardiac Failure, 2020, 26, 662-663.	0.7	0
366	SO057BETA-BLOCKERS ARE ASSOCIATED WITH REDUCED MORTALITY IN PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION AND ADVANCED CHRONIC KIDNEY DISEASE: COHORT STUDY. Nephrology Dialysis Transplantation, 2020, 35, .	0.4	0
367	Do chronic heart failure patients receive optimal decongestive interventions in a realâ€”life setting?: Reply. European Journal of Heart Failure, 2021, 23, 342-343.	2.9	0
368	Do we need a definition of acute heart failure with preserved ejection fraction?. Annals of Medicine, 2021, 53, 1473-1478.	1.5	0
369	Use of loop diuretics in chronic heart failure: do we adhere to the Hippocratic principle â€”do no harmâ€”. European Journal of Heart Failure, 2021, , .	2.9	0
370	Methodological issues in meta-analyses of real-world clinical data to infer causality. International Journal of Cardiology, 2021, 345, 107-108.	0.8	0
371	Left Ventricular Assist Devices: From Bridge to Transplant to Destination Therapy. , 2013, , 385-423.		0
372	Abstract 12273: Benefits and Safety of Prolonged Dual Antiplatelet Therapy in Patients With Ischemic Cardiovascular Disease: A Meta-analysis of 18 Randomized Trials Including 94,306 Patients. Circulation, 2015, 132, .	1.6	0
373	Abstract 12849: Changes in N-terminal Pro Brain Natriuretic Peptide Levels Predicts Mortality and Heart Failure Hospitalization in Patients With Heart Failure and Preserved Ejection Fraction. Circulation, 2015, 132, .	1.6	0
374	Effectiveness of cardiovascular implantable electronic devices with a defibrillator component therapy according to ventricular assist device implant strategy: data from the PCHF-VAD registry. Cardiologia Croatica, 2018, 13, 358-360.	0.0	0
375	Improving outcomes in heart failure requires improving implementation of heart failure therapy. Polish Archives of Internal Medicine, 2019, 129, 869-870.	0.3	0
376	Induction Therapy after Heart Transplantation. Journal of Heart and Lung Transplantation, 2020, 39, S277.	0.3	0
377	Association between use of beta-blockers and mortality/morbidity in patients with heart failure with reduced, midrange or preserved ejection fraction and advanced chronic kidney disease. European Heart Journal, 2020, 41, .	1.0	0
378	Treatment with sacubitril/valsartan in European outpatients with chronic heart failure in Europe: results from ARIADNE registry. European Heart Journal, 2020, 41, .	1.0	0

#	ARTICLE	IF	CITATIONS
379	Comparison of various instantaneous pulmonary arterial wedge pressure measurements with prognostic validation. <i>European Heart Journal</i> , 2020, 41, .	1.0	0
380	An epigenetic circuit linking oxidative stress and DNA hydroxymethylation in heart failure. <i>European Heart Journal</i> , 2020, 41, .	1.0	0
381	Baseline characteristics and clinical features of patients with heart failure with reduced ejection fraction: a European real-world, non-interventional registry study. <i>European Heart Journal</i> , 2020, 41, .	1.0	0
382	Safety of sacubitril/valsartan in heart failure outpatients with chronic heart failure in real life in Europe: results from ARIADNE registry. <i>European Heart Journal</i> , 2020, 41, .	1.0	0
383	Death, hospitalization, emergency department visits and out-patient visits in patients with heart failure in contemporary practice: results from the prospective European 9069-patient ARIADNE registry. <i>European Heart Journal</i> , 2020, 41, .	1.0	0
384	297â€fEchocardiographic biventricular coupling index to predict pre-capillary pulmonary hypertension. <i>European Heart Journal Supplements</i> , 2021, 23, .	0.0	0